TriangleTumour biology
- Alterations, tiered and evidenced
- Copy number, variants, and fusions
- Gene expression
- Mutational burden and MSI
- Mutational signatures
Evidence
Knowledge is power. Here’s the evidence.
The more a patient and their team know, the better they do. Medicine keeps finding it, trial after trial. Cited in full below, limits included.
3×higher response rate31% median response rate with biomarker selection, versus 10.5% without. An across-trial comparison, not a randomized one.570 phase II studies · 32,149 patients · Schwaederle et al., JCO, 2015This is why the deep analysis starts from your biology.
1 in 5patients found a mistake in their own recordsAmong patients who read their clinical notes, 21% reported an error; 42% of those were serious.22,889 note readers · 3 US health systems · Bell et al., JAMA Network Open, 2020It’s also why reading your record is free.
58%lower risk of developing type 2 diabetesNot cancer; what matters is what informed patients do next. Intensive lifestyle coaching versus placebo; metformin cut risk 31%.3,234 adults with prediabetes · Knowler et al., NEJM, 2002And why Triangle reads beyond one disease.
Triangle is built on this premise. Start with your own file →
What the analysis connects
One analysis. A broader view of what’s in your file.
Triangle connects your records and supported sequencing before you ask a question, then turns the results into a reading you can trace back to its sources.
Accredited laboratories do the sequencing. Triangle re-analyses supported data for research use with established tools. What runs depends on what is available in your file.
01 · Your fileRecords + supported sequencing
02 · AnalysisA staged analysis with established tools
03 · Your readingA sourced reading + visible gaps
Immune & inherited context
- HLA type and loss
- Immune cell estimates
- Neoantigen candidates
- Pathway enrichment
- Germline signals for follow-up
Options to discuss
- Targeted-therapy evidence
- Relevant clinical-trial candidates
- Drug-metabolism context
- Supplement interactions to discuss
What’s included depends on the records and sequencing data available in your file. Evidence sources include peer-reviewed literature, FDA labelling, NCCN guidelines, and public trial registries.
See examples of the analysis tools
BWA-MEM2 · GATK · Manta · PureCN · STAR · Salmon · Arriba · OptiType · MHCflurry
The second look, measured
A second reading changes cases.
None of these studies tested Triangle. Nothing has yet; we are new. They test the premise it is built on: the second, complete look is where findings live. We will publish our own numbers as they accrue: review turnaround, corrections issued, what a run surfaced that the chart missed.
12%
of first diagnoses survived a second opinion unchanged
Of 286 cases carried to a second clinic, 21% emerged distinctly different and 66% better defined.
286 referrals · Van Such et al., J Eval Clin Pract, 2017
⅓
less progression when treatment matched the tumour’s biology
Patients on closely matched therapy progressed more slowly and lived longer. Observational, single centre.
429 evaluable patients · Kato et al., Nature Communications, 2020
8%
of cancer patients ever join a trial
For 56 of every 100, no trial was open where they were treated. The barrier is the system, not the patient.
13 studies · 8,883 patients · Unger et al., JNCI, 2019